Zenas BioPharma (NASDAQ:ZBIO) Shares Up 7.7% – Time to Buy?

Zenas BioPharma, Inc. (NASDAQ:ZBIO) shares shot up 7.7% during trading on Monday . The stock traded as high as $20.73 and last traded at $20.8450. 89,357 shares changed hands during mid-day trading, a decline of 90% from the average session volume of 893,604 shares. The stock had previously closed at $19.36.

Wall Street Analysts Forecast Growth

Several research firms have commented on ZBIO. Guggenheim lifted their price target on Zenas BioPharma from $45.00 to $55.00 and gave the company a “buy” rating in a report on Monday, March 16th. HC Wainwright restated a “buy” rating and issued a $44.00 price target on shares of Zenas BioPharma in a report on Tuesday, March 17th. Morgan Stanley lifted their price target on Zenas BioPharma from $19.00 to $21.00 and gave the company an “equal weight” rating in a report on Tuesday, March 17th. Citigroup decreased their target price on Zenas BioPharma from $43.00 to $41.00 and set a “buy” rating for the company in a report on Tuesday, March 17th. Finally, Jefferies Financial Group reiterated a “buy” rating and set a $48.00 target price on shares of Zenas BioPharma in a report on Tuesday, January 6th. Six research analysts have rated the stock with a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, Zenas BioPharma currently has a consensus rating of “Hold” and an average target price of $44.14.

Zenas BioPharma Stock Up 0.3%

The company has a debt-to-equity ratio of 0.32, a quick ratio of 5.61 and a current ratio of 5.61. The firm has a market cap of $1.20 billion, a PE ratio of -2.67 and a beta of -0.61. The stock has a fifty day moving average price of $22.12 and a 200-day moving average price of $27.03.

Zenas BioPharma (NASDAQ:ZBIO) last released its quarterly earnings results on Monday, April 13th. The company reported ($1.10) earnings per share for the quarter. Research analysts expect that Zenas BioPharma, Inc. will post -4.97 EPS for the current year.

Insider Buying and Selling

In related news, Director Fairmount Funds Management Llc purchased 150,000 shares of the firm’s stock in a transaction on Tuesday, March 31st. The stock was purchased at an average price of $20.00 per share, for a total transaction of $3,000,000.00. Following the acquisition, the director directly owned 2,359,025 shares in the company, valued at $47,180,500. The trade was a 6.79% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Patricia L. Allen purchased 15,700 shares of the firm’s stock in a transaction on Thursday, February 12th. The stock was bought at an average price of $24.85 per share, with a total value of $390,145.00. Following the acquisition, the director owned 15,700 shares in the company, valued at $390,145. This trade represents a ∞ increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders have bought 259,613 shares of company stock worth $5,221,863 in the last 90 days. 22.00% of the stock is owned by insiders.

Hedge Funds Weigh In On Zenas BioPharma

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Quarry LP boosted its holdings in Zenas BioPharma by 34.5% in the 3rd quarter. Quarry LP now owns 1,134 shares of the company’s stock worth $25,000 after acquiring an additional 291 shares during the period. Deutsche Bank AG boosted its holdings in Zenas BioPharma by 4.5% in the 4th quarter. Deutsche Bank AG now owns 12,781 shares of the company’s stock worth $464,000 after acquiring an additional 554 shares during the period. CWM LLC raised its position in shares of Zenas BioPharma by 48.3% in the 4th quarter. CWM LLC now owns 2,178 shares of the company’s stock valued at $79,000 after purchasing an additional 709 shares in the last quarter. Two Sigma Investments LP raised its position in shares of Zenas BioPharma by 3.9% in the 3rd quarter. Two Sigma Investments LP now owns 20,382 shares of the company’s stock valued at $452,000 after purchasing an additional 765 shares in the last quarter. Finally, Bank of America Corp DE raised its position in shares of Zenas BioPharma by 5.8% in the 3rd quarter. Bank of America Corp DE now owns 14,809 shares of the company’s stock valued at $329,000 after purchasing an additional 818 shares in the last quarter.

About Zenas BioPharma

Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.